A recent study by the FDA about the drug Byetta, formulated to treat patients with diabetes type 2, has shown that the drug may be the cause of acute pancreatitis, an inflammation of the pancreas that can be fatal to the victim. Byetta, also known as Exenatide, is currently manufactured by Eli Lilly and Company and Amylin Pharmaceuticals.
These companies took a big hit this Tuesday as a result of the study done by The Food and Drug Administration. According to the FDA, they have reviewed 30 reports of acute pancreatitis, which they said could be associated with the use of Byetta. The agency also said "Amylin has agreed to update Byetta's label to discuss the possibility it could contribute to or cause pancreatitis."
Government regulators also made public warnings. They have stated that doctors should stop patients' use of Byetta if pancreatitis is suspected.” As a response, Amylin’s spokewoman, Alice Bahner Izzo, said the company already has aid information on Byetta’s label, but that it will be revised and updated for clear advice on symptoms and sings patients should look for.